SPP1 and X-linked hypophosphatemia: Boukpessi et al. reported that current therapies for XLH addressing serum phosphate levels and 1,25-dihydroxyvitamin D levels might not influence the osteopontin-induced hypomineralization defect locally in the extracellular matrix of bone and teeth [41].